Introduction
============

Mexico faces a critical epidemic of noncommunicable diseases (NCDs), especially type 2 diabetes mellitus (T2DM), lipid disorders, hypertension, and obesity. Unlike many common infectious diseases that Mexico faced in the past century, NCDs can only be managed and not cured with specific medication or therapy. However, it has been estimated that 95% of this NCD management[@b1-dmso-10-443] is performed outside of medical settings, ie, during a patient's day-to-day life. Although certain direct-to-patient lifestyle interventions have been successful, these interventions are difficult to implement effectively in routine primary care and yield heterogeneous results.[@b2-dmso-10-443]

The question becomes how primary care clinics can empower, educate, and motivate patients to take an active role in the management of their NCD(s). It is well known that diabetes knowledge and health literacy are the cornerstone for making decisions on self-management; there is a significant association between T2DM knowledge and attitudes and self-care (blood glucose monitoring and diet).[@b3-dmso-10-443] Yet, it is still unclear if improved patient knowledge in and of itself is a sufficient condition to have an impact on lifestyles, healthy behaviors, and self-management activities.[@b4-dmso-10-443] It is even less clear if these have an impact on patient health outcomes.

It is also unclear logistically how health care professionals (HCPs) can increase patient knowledge and self-management activities within the context of primary care practice given current constraints. A significant challenge to improved patient knowledge is that the Mexican medical education system does not train future HCPs on educational communication, supporting healthy behavior strategies, or building egalitarian patient--provider relationships.[@b5-dmso-10-443]

One comprehensive intervention that has attempted to permeate the primary health care level and overcome this HCP-training barrier is the CASALUD Model, described in detail elsewhere.[@b6-dmso-10-443] It is a primary care model created by the "Fundación Carlos Slim" \[Carlos Slim Foundation\]. The CASALUD Model was designed for state clinics operating with funding from "Seguro Popular", the universal health insurance offered to all Mexican residents not covered by other public insurance systems.

CASALUD's capacity-building pillar is carried out through the computer-based Online Interactive Platform for Health Education (called PIEENSO for its initials in Spanish). In general, physicians have shown improved satisfaction and knowledge with online continuing medical education (CME) programs that include interactivity, practice exercises, repetition, and feedback.[@b7-dmso-10-443] PIEENSO includes all of these components and is able to function with or without an Internet connection, allowing HCP access even in rural areas.

This CME program offers the following two certificates: a 110-hour Online Certificate, which updates HCP knowledge on NCDs and current evidence-based NCD prevention, treatment, and management strategies (including how to deliver diabetes self-management education \[DSME\]) and a Competencies Certification, a 40-hour course in which physicians solve real-life cases to test their knowledge in practical settings. As of May 2016, 224 HCPs from the two studied states had participated in CASALUD's CME program by completing the Online Certificate and/or the Competencies Certification.

The objective of this study was to track how online CME provided to HCPs at primary health care centers (PHCs) through the CASALUD Model impacted the patient--provider "educational chain". This chain, along with other factors that influence patient health, is shown in [Figure 1](#f1-dmso-10-443){ref-type="fig"}. Detailed descriptions of the components of each link in the chain can be found in the following section.

While CASALUD addresses issues with medication supply, availability of laboratory tests, clinic infrastructure, and of course HCP training, it is important to keep in mind that other medical, health care, and personal factors influence patient disease biomarkers. This article limits itself to exploring the educational chain that may theoretically connect HCP training with patient health.

The educational chain is defined as a series of conditions that begins with HCP training. This can prompt more co-responsible health care -- understood as a relationship with equal responsibility between providers, patients, and the community -- especially shared decision-making and DSME.[@b8-dmso-10-443] This improved health care brings about increased patient health knowledge, which is subsequently acted upon through healthier self-management activities. At the end of the educational chain, if all of the prior conditions are present, one might expect to see an improvement in patient health (measured through disease biomarkers). To test this hypothesis, patient disease biomarkers were also tracked over the course of the 3-year study in order to observe the effects that the educational chain might have had on patient health.

Methods
=======

A total of 422 patients participated in an observational, 3-year longitudinal study. The purpose of the study was to observe the influence of the online CME delivered through the capacity-building pillar of CASALUD on the quality of health care, patient knowledge, disease self-management activities, and patient disease biomarkers. This study was not designed to be a representative sample of all CASALUD clinics in Mexico; rather, the objective was to closely follow a group of patients receiving care through the CASALUD Model in order to better understand their experiences.

The group of patients included in this study was defined in close consultation with participant PHCs: eight PHCs from two central Mexican states where the CASALUD Model had been implemented. First, the participant PHCs proposed a list of all active seekers of PHC health care services with a previous diagnosis of at least one NCD (T2DM, hypertension, or a lipid disorder). Of the patients on these lists, clinic HCPs invited all patients who were contactable to participate in this study; if a patient requested further details, he or she was contacted by study researchers. This strategy was followed until the sample size was reached. The sample size was designed to permit the detection of changes of 0.5% in glycated hemoglobin (A1C) levels at a confidence level of 95% while taking possible desertions into account.

Patients were excluded if they moved out of the study area, were no longer covered under the studied health system (Seguro Popular), withdrew consent, passed away, or were otherwise unable to attend data collection events. They were considered lost to follow-up if they were not contactable or failed to present at a PHC during data collection events, despite numerous attempts to contact.

Data collection began in April 2013, when patients signed informed consent; follow-up surveys occurred during April--May 2014 and 2015, when patients gave verbal assent. Participants were provided with the results and interpretation of all laboratory tests, as well as a complimentary breakfast on the day of data collection.

Sixty-one participants were lost to follow-up or excluded between 2013 and 2014, and 51 participants between 2014 and 2015, slightly \>20% of the originally recruited participants ([Figure 2](#f2-dmso-10-443){ref-type="fig"}). Patients reporting kidney failure at any point during data collection were eliminated from the study, as national guidelines call for these patients to be referred to secondary care. As CASALUD is a general primary care model and does not contemplate patients with severe complications, these patients should not fall under the CASALUD Model.

Although all patients were analyzed together, they were also grouped by individual disease; detailed criteria on group composition are available in [Table S1](#SD1-dmso-10-443){ref-type="supplementary-material"}.

Data for the first three links in the educational chain were collected with a questionnaire designed to capture perceptions of health care, diabetes patient health knowledge, and self-reported disease self-management activities. In the questionnaire, one group of questions corresponded to perceived quality of health care, one group of questions corresponded to patient disease knowledge, and one group of questions corresponded to chronic disease self-management activities. Each of these groups was further divided into subgroups. Perceived quality of care was divided into three subgroups: technical quality of care, interpersonal quality of care, and availability of care, while patient disease knowledge was divided into T2DM risk calculation and T2DM knowledge. The last group of T2DM self-management activities was divided into glucometer, medication and treatments, self-care activities, and no tobacco/alcohol use.

Indexes were created with the concept of unidimensional distance; values are presented on a scale ranging from 0 to 1, where 0 is the complete absence of affirmative responses to that set of questions and 1 means that all patients responded affirmatively. The questions used to define each group or subgroup, along with a more detailed description of how the indexes were constructed, can be found in [Tables S2](#SD2-dmso-10-443){ref-type="supplementary-material"}[](#SD3-dmso-10-443){ref-type="supplementary-material"}--[S4](#SD4-dmso-10-443){ref-type="supplementary-material"}.

Blood samples were collected to measure A1C, triglycerides, and cholesterol, which were all analyzed by photometry with a cobas c 111 analyzer. Blood pressure measurements were performed using an Omron Brand Automatic Blood Pressure Monitor, weight was measured using the Camry EB9015 scale, and height and waist circumference were measured using a PRETUL Tape Measurer. Blood pressure, height, and weight were measured twice, or three times in the case of discrepancy.

Results
=======

The average age of participants at the beginning of data collection was 56.3 years. In line with gender distribution of the general patient population in Seguro Popular PHCs,[@b9-dmso-10-443] the group of participants was also predominantly female (81.8%). Descriptive (age) and frequency (gender and socioeconomic level) variables are presented in [Table 1](#t1-dmso-10-443){ref-type="table"}. The majority of the participants were classified as belonging to lower (D, 46.9%) or lower-middle socioeconomic levels (D+, 23.7%). Socioeconomic levels were measured with criteria defined by the Mexican Association of Marketing Research and Public Opinion Agencies (AMAI, in Spanish). The AMAI instrument uses 13 questions on educational attainment, household conditions, and ownership of certain belongings -- such as a personal computer and automobile -- in order to classify households into one of the five levels.

The vast majority of the participants (83.2%) met the International Diabetes Federation criteria for metabolic syndrome at the beginning of the study,[@b10-dmso-10-443] as shown in [Table S5](#SD5-dmso-10-443){ref-type="supplementary-material"}. This speaks to a population of complicated comorbidities. Indeed, at baseline, only 43.3% of patients with T2DM had their disease under control (A1C \<7% or 53 mmol/mol). Many patients with T2DM had a long-term diagnosis, having been diagnosed either between 5 and 10 years (24.0%) or \>10 years (31.8%) prior to the study.

Change in indexes was measured through a repeated measures analysis of variance (ANOVA), which tests for changes over time in a single population.[@b11-dmso-10-443] This test revealed that some indexes of each link of the educational chain remained relatively stable throughout the 3 years, while clear increases were observed in certain subgroups and groups. These changes are described below and presented visually in [Figures 3](#f3-dmso-10-443){ref-type="fig"}[](#f4-dmso-10-443){ref-type="fig"}--[5](#f5-dmso-10-443){ref-type="fig"}, with descriptive and analytic statistical information presented in [Table 2](#t2-dmso-10-443){ref-type="table"}.

The perceived quality of health care was the group of indicators that saw the most statistically significant increases in aggregate, as well as in the majority of its subgroups (shown in [Figure 3](#f3-dmso-10-443){ref-type="fig"}). The subgroup that saw the most improvement was interpersonal quality of care, which comprised four questions directed toward patient--provider communication and shared decision-making. During the timeframe that CASALUD's CME program was implemented (2013--2015), this index rose from 0.54 to 0.73 (*P*\<0.001). Technical quality of care also increased significantly during this same time period. Due to these important increases, the total group score rose significantly from 0.54 to 0.64 in the 2 years following the implementation of the CASALUD's online CME program (*P*\<0.001).

Improvements in indicators of quality of health care were reflected in patient health knowledge: the overall group score increased moderately but significantly from 0.80 at baseline to 0.84 at Year 2 (*P*\<0.001). Both subgroups, T2DM knowledge and T2DM risk calculation, increased in the greatest proportion between 2013 and 2014 ([Figure 4](#f4-dmso-10-443){ref-type="fig"}). The proportion of patients correctly reporting that T2DM is a risk factor for blindness, stroke, amputation, and other common complications was high at the commencement of the study and increased further.

Moving to the next link in the chain, the overall group index of diabetes self-management activities rose from 0.62 in 2013 to 0.67 in 2015 (*P*\<0.001), as shown in [Figure 5](#f5-dmso-10-443){ref-type="fig"}. Most important was the fact that significantly more patients reported owning and using a glucometer, as well as participating in self-care activities. The subgroup of self-care activities comprised exercising, following a healthy eating plan, checking their own bare feet, involving their family in care, and belonging to a peer support group at their PHC. Self-reported medication adherence and abstention from tobacco and alcohol were high at study commencement and remained stable throughout the study period.

The disease biomarker average, in general, remained unchanged over the course of the study. No significant changes were observed in lipid levels or in the percentage of patients with this diagnosis who had their disease under control. Although average body mass index (BMI) did not change significantly, the percentage of patients who were able to lose enough weight to fall within a normal range was important: 10.3% of participants who began with BMI \>30 were able to move below that level by 2015 (*P*\<0.001).

The mean levels of two types of disease biomarkers changed significantly: A1C levels and blood pressure. A1C levels increased between 2013 and 2015 from 7.95 to 8.41% (63--68 mmol/mol) (*P*\<0.001), and the percentage of patients with A1C \>7% (53 mmol/mol) decreased from 43.3% to 34.0% (*P*\<0.001). As a reference, people with diabetes on constant monotherapy typically experience an increase in A1C levels of \~1% every 2 years.[@b12-dmso-10-443] Blood pressure decreased significantly between 2014 and 2015 from 143.7/76.8 to 137.5/74.4 (systolic/diastolic reported in mmHg). Detailed numbers by year are presented in [Table 3](#t3-dmso-10-443){ref-type="table"}, and further discussion on the significance of these findings is included in the following section.

Discussion
==========

While other articles have explored individual connections between HCP education, quality of care, patient knowledge, disease self-management activities, and disease biomarkers, this is, to our knowledge, the first paper to present these categories as a chain. We propose this theoretical structure in order to better identify why certain studies have found connections between categories and others have not. While this chain has not yet been validated, the authors hypothesize that each link may have a significant impact on the links further down the chain (as shown in [Figure 6](#f6-dmso-10-443){ref-type="fig"}).

The strongest increases in indicators were seen in the quality of health care (technical quality of care and interpersonal quality of care). This is not surprising, as CASALUD's capacity-building pillar focuses on aligning the care provided in Seguro Popular clinics with Mexican federal government standards of care and clinical practice guidelines. This pillar is also heavily concentrated on instilling the importance of patient-centered care and patient co-responsibility. While there is no clear definition of interpersonal quality of care in the literature yet,[@b13-dmso-10-443] it is clear that communication and shared decision-making have an important impact on patient treatment adherence and therapeutic behavior changes.[@b14-dmso-10-443]

Levels of knowledge regarding T2DM care (such as target A1C levels) were low at baseline, and rose significantly by Year 2. Improvements in quality of health care -- including DSME, provider communication, and shared decision-making -- may have led to this significant increase in T2DM knowledge. The PIEENSO courses specifically train HCPs on how to deliver DSME to their patients, and the authors propose that DSME was an important intermediate link between quality of health care and diabetes patient health knowledge.

Patient health knowledge was acted on, as seen in the significant improvements in the overall group of disease self-management activities. The most important increases were seen in owning and using a glucometer and participating in self-care activities. Perceived and objective quality of care can have an important impact on patients' self-management abilities. In this case, increased medical quality, specifically DSME and joint patient--provider decision-making, may prompt patients to take a greater role in their own disease management. Indeed, regular intervention built on existing, longstanding primary care relationships may have a significant impact on patients[@b15-dmso-10-443] and patient--provider relationships have been shown to have a direct impact on T2DM management attitudes and adherence to diet and exercise plans.[@b16-dmso-10-443]

While positive results were seen in the first three links of the chain, this was not reflected in significant changes in biomarkers across all variables. This is in line with other studies that have attempted to train primary care providers in delivering DSME and lifestyle interventions. While these studies typically find great improvements in provider satisfaction, knowledge, and practice change, there is little existing evidence on how online HCP CME can affect patient outcomes.[@b7-dmso-10-443] Indeed, a systematic review found that the strength of evidence between care quality, patient health literacy, and self-management was insufficient for glycemic control and low for hypertension.[@b4-dmso-10-443] Significantly, 83% of our study population had metabolic syndrome, only 44% of patients with T2DM had their disease under control, and 56% had been diagnosed with T2DM over 5 years prior to the study. Patients with longstanding chronic diseases tend to respond less (in terms of biomarkers) to lifestyle interventions.[@b17-dmso-10-443]

Improvements in blood pressure drew our attention, and other Mexican authors studying NCDs in Seguro Popular clinics have noted a similar phenomenon: control of blood pressure is more common than control of diabetes.[@b18-dmso-10-443] Anecdotal reports from HCPs suggest that blood pressure drugs are better stocked in the PHC pharmacies and of higher quality than available glucose-lowering medications. Hypertension can also be more sensitive to diet and physical activity: the ENCORE study saw improvements of 16.1 mmHg in systolic blood pressure with diet alone.[@b19-dmso-10-443]

The lack of statistically significant positive improvements in other disease biomarkers, especially A1C, has been observed in multidisciplinary interventions. The impact of long-term patient education (\>6 months) delivered by HCPs in a primary care setting on NCD disease outcomes is still not completely understood.[@b13-dmso-10-443],[@b20-dmso-10-443] Training nurses, and even specialized therapists and multidisciplinary teams, on broad educational interventions is generally not able to sustain improvements in biomarkers between treatment and control groups of diabetes patients.[@b21-dmso-10-443] This is because, in order to see results in a specific educational chain, educational programs should be targeted and disease specific instead of more generalized "lifestyle" educational programs. This was demonstrated by the recent CASCADE and DEPICTED studies, which tested group education programs for physicians and pediatric clinics to improve long-term glycemic control in their patients, without observing significant differences.[@b22-dmso-10-443],[@b23-dmso-10-443] Most importantly, it has been shown that HCPs require continual feedback and technical support to maintain the skills learned through training sessions.[@b24-dmso-10-443] Online CME linked to DSME may be the best option to train HCPs on disease-specific education and training, so that persons with diabetes can maintain the benefits of this training in the long term.

Time plays an important role in disease biomarkers, and it is possible that 2 years was too short of a time period to begin to see significant changes.[@b25-dmso-10-443] While a systematic review on multifactorial lifestyle interventions found no consistent effects on disease biomarkers in the short term, they did find differences in longer term outcomes, such as cardiac events and mortality.[@b2-dmso-10-443] Interestingly, the lack of significant differences in disease biomarkers may be losing importance in the current discourse. A new wave of authors is starting to question the value of solely focusing on disease biomarkers, especially A1C, as this can cause overmedication and poly-pharmacy, with associated side effects.[@b26-dmso-10-443],[@b27-dmso-10-443] Even if complications are reduced through tight A1C control, they may not be clinically significant (as in the case of retinopathy).[@b28-dmso-10-443] Rather, newer interventions should focus on improving quality of life and reducing complications as well as overall costs to health care systems.[@b21-dmso-10-443]

The principal limitation of this study is the uneven implementation of the CASALUD Model. For example, not all medical providers took the Online Certificate at the same time -- 79% signed up in 2013 and the rest in 2014 and 2015. Another important limitation was the lack of a control group and the fact that those participants who were lost to follow-up were not included in this study. Significant differences (*P*\<0.001) were found between "completers" and "deserters", with geographical differences and more men in the deserter group (the completer group was 81.8% female while the deserter group was 64.3% female). However, no differences were found in their responses to the questionnaire or biomarkers, which leads us to conclude that the results presented here were not swayed by their withdrawal from the study. Additionally, the authors recognize a possible source of bias in how the first three links in the chain were tracked: as this was a general study of CASALUD and patients' time was limited, more extensive monitoring of diet, physical activity, and drug adherence (eg, with specialized instruments) was not possible. The first three links in the chain were therefore monitored with self-reports, which means that these data could contain a degree of response bias, specifically social desirability bias. In the same vein, it was not possible to measure how HCPs educated individual patients or which treatment guidelines they used to treat individual patients. This includes prescribing behavior or NCD management strategies, including what criteria physicians used to prescribe glucose-lowering drugs/insulin, statins, and blood pressure-lowering medication to their patients.

Implications
============

This study has shown the feasibility of using an online CME program, such as the CASALUD Model's PIEENSO platform, to deliver HCP education at a clinic level throughout a country. This is of great significance, as CME that trains on comprehensive educational and patient-focused interventions may be one of the most viable options to address NCDs and other lifestyle diseases at the primary care level. Other authors have shown that the quality of online CME is non-inferior to in-person CME and is a viable option, especially for lesser-developed regions where traveling to live CME events may be complicated.[@b29-dmso-10-443] CME programs' relative low cost, ability to be completed at HCPs' convenience, and accessibility make them even more attractive.

Online CME programs are also more easily converted into ongoing training programs, which are crucial to maintaining consistently high-quality NCD management. Due to high HCP turnover and a need for continuous feedback, one-time training programs on general lifestyle interventions should be converted into continual training programs. Online programs such as the capacity-building pillar of CASALUD could be integrated into ongoing PHC human resources training to assure full coverage and better serve the clinical environment.

This study shows that online CME for HCPs can effect specific changes in the educational chain linking quality of health care, patient knowledge, and self-management behaviors. This is the first study to present the impact of online CME on the entire educational chain, as well as on disease biomarkers. Importantly, this article puts forth the theory that the impact of educational chains on patient disease biomarkers is multidimensional: factors unrelated to CME can also affect or even confound the results of educational interventions.

Supplementary materials
=======================

Index construction with three evaluated groups and their nine subgroups
-----------------------------------------------------------------------

Variables were dichotomous dummy variables; the aggregated sum was obtained for each of the three groups and the corresponding nine subgroups using the following formula: $$\frac{\sum_{i = 1}^{n}{d_{i} - \text{Min}\left( {\sum_{i = 1}^{n}d_{i}} \right)}}{\text{Max}\left( {\sum_{i = 1}^{n}d_{i}} \right) - \text{Min}\left( {\sum_{i = 1}^{n}d_{i}} \right)},$$where d is dummy. Values were normalized with unidimensional distance in function of the operationalization.

###### 

Criteria to define diagnosis of NCD

  ----------------------------------------------------------------------------------------------------------------------------------
  Condition         N     Group composition
  ----------------- ----- ----------------------------------------------------------------------------------------------------------
  Diabetes          283   Patients reporting prior diagnosis of T2DM on at least two occasions during data collection\
                          Patients with A1C levels \>7%\
                          Patients with a diagnosis of T2DM registered in the FCS's electronic medical record system\
                          Elimination of extreme outliers (A1C \>15% at any wave of data collection)

  Hypertension      269   Patients reporting prior diagnosis of hypertension on at least two occasions during data collection\
                          Patients with diastolic blood pressure \>80 mmHg and/or systolic pressure \>120 mmHg\
                          Patients with a diagnosis of hypertension registered in the FCS's electronic medical record system\
                          Elimination of patients with data capture errors (negative values)

  Obesity           165   Patients with body mass index \>30 in 2013

  Lipid disorders   249   Patients reporting prior diagnosis of a lipid disorder on at least two occasions during data collection\
                          Patients with total cholesterol \>200 and/or triglycerides \>150 at any wave of data collection
  ----------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** FCS, Fundación Carlos Slim; NCD, noncommunicable disease; T2DM, type 2 diabetes mellitus.

###### 

Patient health knowledge

  --------------------------------------------------------------------------------------------------------------------------
  Diabetes risk calculation                     Diabetes health literacy
  --------------------------------------------- ----------------------------------------------------------------------------
  A person with diabetes has a high risk of:\   6\. Diabetes can be hereditary\
  1. Heart attack\                              7. Diabetes can cause loss of feeling in hands, fingers, feet, and toes\
  2. Stroke\                                    8. For someone with diabetes, their goal should be to have A1C levels \<7%
  3. Becoming blind\                            
  4. Requiring an amputation\                   
  5. Permanent kidney damage                    

  --------------------------------------------------------------------------------------------------------------------------

###### 

Disease self-management activities

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Glucometer                                                                       No tobacco/alcohol use
  -------------------------------------------------------------------------------- --------------------------------------------------------------------------
  1\. Have a glucometer.\                                                          4\. Do not drink alcohol.\
  2. Use their glucometer (of those reporting ownership of a glucometer, n=90).\   5. Do not smoke tobacco.
  3. Keep a daily log of their glucose levels.                                     

                                                                                   

  **Medication and treatments**                                                    **Self-care activities**

                                                                                   

  6\. Take anti-hyperglycemic agents for diabetes.\                                11\. Follow a healthy eating plan \>3 days a week.\
  7. Regularly inject insulin (of those reporting insulin prescription, n=116).\   12. Report that the people they live with help them with their disease.\
  8. Take their medication on schedule.\                                           13. Check their own bare feet.\
  9. Go to their scheduled follow-up appointments.\                                14. Exercise.\
  10. Use reminders to help adhere to their treatment.                             15. Are part of a disease peer support group at their health center.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Perception of quality of medical care

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Technical quality of care                                                          Interpersonal quality of care
  ---------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  1\. Their doctor ordered an A1C test within the last 3 months.\                    11\. Their doctor explains tests and results.\
  2. Their doctor ordered a urine test within the last 3 months.\                    12. Their doctor communicates in a clear, straightforward manner during office visits.\
  3. The PHC performs an A1C test every 3--6 months.\                                13. They make treatment decisions together with their doctor.\
  4. Their doctor has ever prescribed insulin.\                                      14. Patient and doctor analyze together how to achieve treatment adherence.
  5. Their eyes were checked during their last clinic visit.\                        
  6. Their bare feet were checked during their last clinic visit.\                   
  7. Their glucose levels were checked during their last clinic visit.\              
  8. Their doctor prescribed an exercise plan within the last 3 months.\             
  9. Their doctor prescribed a diet within the last 3 months.\                       
  10. Their blood pressure was checked during their last clinic visit.               

  **Availability of care**                                                           

  15\. During the last 6 months, they had problems to see their doctor.\             
  16. During the last 6 months, they were referred to a specialist or a hospital.\   
  17. Have had full drug supply during the last 3 months.                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviation:** PHC, primary health care center.

###### 

The IDF consensus worldwide definition of the metabolic syndrome

  -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Central obesity (defined as waist circumference) with any two of the following four factors                          
  Raised triglycerides                                                                                                 ≥150 mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality
  Reduced HDL cholesterol                                                                                              \<40 mg/dL (1.03 mmol/L) in males
  \<50 mg/dL (1.29 mmol/L) in females or specific treatment for this lipid abnormality                                 
  Raised blood pressure                                                                                                Systolic BP ≥130 mmHg or diastolic BP ≥85 mmHg or treatment of previously diagnosed hypertension
  Raised fasting plasma glucose                                                                                        FPG ≥100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes
  If \>5.6 mmol/L or 100 mg/dL, OGTT is strongly recommended but is not necessary to define presence of the syndrome   
  -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------

**Abbreviations:** BP, blood pressure; FPG: fasting plasma glucose; IDF, International Diabetes Federation; OGTT, oral glucose tolerance test.
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![Educational chain and other factors that affect patient health.\
**Notes:** Solid lines correspond to aspects addressed through the CASALUD Model, while the dashed line corresponds to other factors that fall outside the scope of this care model.](dmso-10-443Fig1){#f1-dmso-10-443}

![Patient flow diagram.\
**Notes:** Most patients in the "Others" category were those who were not able to take time off from work or were out of the area during the entire duration of the study period, either on vacations or for work. A smaller group of patients in the "Others" category reported either health or transportation issues that made it difficult to visit the PHC where data collection events took place.\
**Abbreviations:** NCD, noncommunicable disease; PHC, primary health care center; T2DM, type 2 diabetes mellitus.](dmso-10-443Fig2){#f2-dmso-10-443}

![Quality of health care.\
**Notes:** The double asterisk (\*\*) following the name of a group or subgroup corresponds to a *P*-value of \<0.01 obtained from performing a repeated measures analysis of variance (ANOVA). If the ANOVA revealed significant differences, a post-hoc analysis was performed, using a Bonferroni correction, to find differences between years. The results are shown in the graphs, marked with the following letters: ^a^Significant difference (*P*\<0.05) between 2013 and the year shown on the × axis (either 2014 or 2015). ^b^Significant difference (*P*\<0.05) between 2014 and 2015.](dmso-10-443Fig3){#f3-dmso-10-443}

![Diabetes patient health knowledge.\
**Notes:** The double asterisk (\*\*) following the name of a group or subgroup corresponds to a *P*-value of \<0.01 obtained from performing a repeated measures analysis of variance (ANOVA). If the ANOVA revealed significant differences, a post-hoc analysis was performed, using a Bonferroni correction, to find differences between years. The results are shown in the graphs, marked with the following letters: ^a^Significant difference (*P*\<0.05) between 2013 and the year shown on the × axis (either 2014 or 2015).](dmso-10-443Fig4){#f4-dmso-10-443}

![Disease self-management activities.\
**Notes:** The double asterisk (\*\*) following the name of a group or subgroup corresponds to a *P*-value of \<0.01 obtained from performing a repeated measures analysis of variance (ANOVA). If the ANOVA revealed significant differences, a post-hoc analysis was performed, using a Bonferroni correction, to find differences between years. The results are shown in the graphs, marked with the following letters: ^a^Significant difference (*P*\<0.05) between 2013 and the year shown on the × axis (either 2014 or 2015). ^b^Significant difference (*P*\<0.05) between 2014 and 2015.](dmso-10-443Fig5){#f5-dmso-10-443}

![Hypothesized linkages between health care, health knowledge, self-management activities, and disease biomarkers (with observed statistically significant changes)\
**Notes:** Bold arrows, outlines in black, and bolded words correspond to statistically significant changes (*P*\<0.01) between 2013 and 2015. Dashed gray lines correspond to changes that did not reach statistical significance.](dmso-10-443Fig6){#f6-dmso-10-443}

###### 

Sociodemographic characteristics at study commencement

  Characteristic            Type of statistic   Other measures
  ------------------------- ------------------- ----------------
  **Age**                   **Mean**            **SD**
   Years                    56.3                12.1
  **Sex**                   **Frequency**       **Percentage**
   Women                    345                 81.8%
   Men                      77                  18.3%
  **Socioeconomic level**   **Frequency**       **Percentage**
   E (lowest)               27                  6.4%
   D                        198                 46.9%
   D+                       100                 23.7%
   C−/C/C+                  95                  22.5%
   A/B (highest)            2                   0.5%

**Notes:** Socioeconomic levels were measured with criteria defined by the Mexican Association of Marketing Research and Public Opinion Agencies (AMAI, in Spanish). The AMAI instrument uses 13 questions on educational attainment, household conditions, and ownership of certain belongings -- such as a personal computer and automobile -- in order to classify households into one of the five levels.

**Abbreviation:** SD, standard deviation.

###### 

Changes in Indexes 2013--2015 with repeated measures analysis of variance

  Group (Subgroups)                        Mean level (standard deviation)   *P*-value                                                                                                                                                                 
  ---------------------------------------- --------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------
  **Quality of health care**               **0.54 (0.18)**                   **0.58[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.18)**       **0.64[a](#tfn4-dmso-10-443){ref-type="table-fn"},[b](#tfn5-dmso-10-443){ref-type="table-fn"} (0.18)**   \<**0.001**
   Technical quality of care               0.55 (0.21)                       0.58 (0.21)                                                      0.62[a](#tfn4-dmso-10-443){ref-type="table-fn"},[b](#tfn5-dmso-10-443){ref-type="table-fn"} (0.20)       \<0.001
   Interpersonal quality of care           0.54 (0.30)                       0.61[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.29)           0.73[a](#tfn4-dmso-10-443){ref-type="table-fn"},[b](#tfn5-dmso-10-443){ref-type="table-fn"} (0.31)       \<0.001
   Availability of care                    0.52 (0.26)                       0.53 (0.26)                                                      0.57 (0.26)                                                                                              0.09
  **Diabetes patient health knowledge**    **0.80 (0.18)**                   **0.85**[a](#tfn4-dmso-10-443){ref-type="table-fn"} **(0.14)**   **0.84**[a](#tfn4-dmso-10-443){ref-type="table-fn"} **(0.14)**                                           \<**0.001**
   Diabetes risk calculation               0.88 (0.23)                       0.94[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.18)           0.92[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.17)                                                   \<0.001
   Diabetes knowledge                      0.66 (0.24)                       0.71[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.21)           0.70[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.20)                                                   \<0.001
  **Disease self-management activities**   **0.62 (0.12)**                   **0.64 (0.13)**                                                  **0.67[a](#tfn4-dmso-10-443){ref-type="table-fn"},[b](#tfn5-dmso-10-443){ref-type="table-fn"} (0.14)**   \<**0.001**
   Glucometer                              0.16 (0.28)                       0.22[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.34)           0.24[a](#tfn4-dmso-10-443){ref-type="table-fn"} (0.38)                                                   \<0.001
   Medication and treatment                0.74 (0.17)                       0.73 (0.18)                                                      0.73 (0.18)                                                                                              0.54
   Self-care activities                    0.65 (0.22)                       0.68 (0.21)                                                      0.75[a](#tfn4-dmso-10-443){ref-type="table-fn"},[b](#tfn5-dmso-10-443){ref-type="table-fn"} (0.21)       \<0.001
   No tobacco or alcohol use               0.95 (0.16)                       0.95 (0.17)                                                      0.94 (0.17)                                                                                              0.75

**Note:** Words in bold correspond to groups and their corresponding measures (mean levels, standard deviations, and *P*-value). Post-hoc pairwise comparisons were performed using Bonferroni's method, revealing:

Significant difference (*P*\<0.05) between 2013 and the year shown in the column title (either 2014 or 2015).

Significant difference (*P*\<0.05) between 2014 and 2015.

###### 

Patient disease biomarkers

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCD (sample size)                                             Disease biomarker/measurement                                  Comparison years (Vertical column versus horizontal)   2013                                     2014                    2015                    ANOVA, *P*-values
  ------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------- ----------------------- ----------------------- -------------------
  **T2DM** (n=283)                                              Mean level (SD) of A1C%                                        **2013**                                               **7.95** (2.11)                          (diff) 0.41\            (diff) 0.47\            *P*\<0.001
                                                                                                                                                                                                                               *P*\<0.001              *P*\<0.001              

  **2014**                                                      --                                                             **8.36** (2.11)                                        (diff) 0.06\                                                                             
                                                                                                                                                                                      *P*=1.00                                                                                 

  **2015**                                                      --                                                             --                                                     **8.41** (2.20)                                                                          

                                                                                                                                                                                                                                                                               

  Percentage in control over the years (A1C \<7%)               N/A                                                            43.26                                                  35.82                                    34.04                   *P*\<0.001              

                                                                                                                                                                                                                                                                               

  **Hypertension** (n=269)                                      Mean level (SD) of Systolic/diastolic blood pressure in mmHg   **2013**                                               **140.79** (23.84)/**75.88** (10.01)     (diff) 2.92/0.87\       (diff) --3.31/--1.45\   *P*\<0.001
                                                                                                                                                                                                                               *P*=0.04/0.33           *P*=0.02/0.03           

  **2014**                                                      --                                                             **143.71** (24.33)/**76.75** (11.09)                   (diff) --6.22/--2.32\                                                                    
                                                                                                                                                                                      *P*\<0.001/0.001                                                                         

  **2015**                                                      --                                                             --                                                     **137.49** (23.96)/**74.43** (10.56)                                                     

                                                                                                                                                                                                                                                                               

  Percentage in control over the years (\<140 and \<90 mmHg)    N/A                                                            51.67                                                  47.58                                    60.22                   *P*\<0.001              

                                                                                                                                                                                                                                                                               

  **Obesity** (n=165)                                           Mean level (SD) of Body Mass Index (kg/m^2^)                   **2013**                                               **34.70** (4.25)                         (diff) --0.37\          (diff) --0.05\          GG\
                                                                                                                                                                                                                               *P*=0.27                *P*=1.00                *P*=0.19

  **2014**                                                      --                                                             **34.33** (4.44)                                       (diff) 0.32\                                                                             
                                                                                                                                                                                      *P*=0.43                                                                                 

  **2015**                                                      --                                                             --                                                     **34.65** (4.45)                                                                         

                                                                                                                                                                                                                                                                               

  Percentage in control over the years (BMI ≤30)                N/A                                                            0.00                                                   9.09                                     10.30                   *P*\<0.001              

                                                                                                                                                                                                                                                                               

  **Lipid Disorder** (n=249)                                    Mean level (SD) of Triglycerides/Total Cholesterol (mg/dL)     **2013**                                               **218.82** (141.23)/**199.22** (37.61)   (diff) --2.98/--0.56\   (diff) 2.43/--2.63\     GG\
                                                                                                                                                                                                                               *P*=1.00/1.00           *P*=1.00/0.763          *P*=0.48

  **2014**                                                      --                                                             **215.84** (140.24)/**198.66** (38.35)                 (diff) 5.40/−2.07\                                                                       
                                                                                                                                                                                      *P*=1.00/1.00                                                                            

  **2015**                                                      --                                                             --                                                     **221.24** (137.43)/**196.59** (35.62)                                                   

                                                                                                                                                                                                                                                                               

  Percentage in control over the years (\<150 and ≤200 mg/dL)   N/A                                                            20.48                                                  28.11                                    20.08                   GG\                     
                                                                                                                                                                                                                                                       *P*=0.022               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Where two identical years intersect, for example 2013 with 2013, the value in the cell corresponds to the average level of that disease biomarker in that year with its standard deviation in parenthesis. When two different years intersect, for example 2013 with 2014, the value in the cell corresponds to the difference between the mean levels of biomarkers between those two years, marked with "diff", and the *P*-value associated with the Bonferroni correction of that year from the ANOVA. In case the assumption of homogeneous sphericity was not fulfilled, the *P*-value reported corresponds to a Greenhouse-Geisser correction (denoted with "GG").

**Abbreviations:** ANOVA, analysis of variance; NCD, noncommunicable disease; T2DM, type 2 diabetes mellitus; BMI, body mass index; SD, standard deviation; mmHg, millimeters of mercury; mg/dL, milligrams per deciliter.
